**Article**

**Perilla Seed Oil Enhances Cognitive Function and Mental Health in Healthy Elderly Japanese Individuals by Enhancing the Biological Antioxidant Potential**

Michio Hashimoto 1,*©, Kentaro Matsuzaki 1©, Shahdat Hossain 1,2, Tomoko Ito 3,4, Harumi Wakatsuki 1, Yoko Tanabe 1, Miho Ohno 5, Setsushi Kato 5, Kazuya Yamashita 3 and Osamu Shido 1

1. Introduction

Aging is an inescapable process characterized by progressive deterioration of physiological integrity leading to functional impairment. Aging is related with cognitive impairment, and age-related memory and cognitive decline are associated with decreased plasma antioxidant levels and increased brain oxidative stress [1]. Although aging is a primary risk factor for several psychiatric disorders, epidemiological evidence suggests that, in humans, diet plays a major role in learning ability and mental health. For example, low levels of ω-3 polyunsaturated fatty acids (PUFA) in the plasma and the brain are associated with the development of dementia in the elderly and in patients with Alzheimer’s disease (AD) [2]. Further, epidemiological studies have shown that ω-3 PUFA deficiency impairs learning and memory [2,3], and is associated with age-related neurodegenerative disorders [3]. Although no noticeable effect of ω-3 PUFA supplementation has been observed in...
patients with AD, several reports suggest that chronic dietary ω-3 PUFA supplementation is effective for some, but not all, elderly people with very mild cognitive impairment or with age-related cognitive decline [4–6]. Studies have shown that ω-3 PUFA-rich foods prevent age-associated cognitive decline in elderly Japanese individuals with cognitive deficits [7]. Therefore, we hypothesized that long-term supplementation of ω-3 PUFA such as α-linolenic acid (LNA), could prevent some of the harmful effects of aging on brain function in the healthy elderly.

Compared to other edible vegetable oils, perilla seed oil (PO) has the highest proportion (54–64%) of LNA (C18:3), which is an essential ω-3 PUFA [8]. LNA is converted to other ω-3 PUFAs such as eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6) in the mammalian liver. However, in humans, the metabolic conversion of LNA to other ω-3 PUFAs, particularly DHA, is very limited [9]. Therefore, it is important to investigate whether dietary LNA could supply EPA and DHA to various tissues. It has been reported that LNA is an antithrombotic [10], antiarrhythmic [11], anti-inflammatory [12], and neuroprotective [13] fatty acid. PO also possesses antidepressant activity, and PO intake improves cognitive ability in rats by producing new hippocampal neural membrane structures as well as by inducing the expression of specific proteins involved in several functions, including regulation of the cytoskeleton, energy metabolism, transport, neurogenesis, and apoptosis [14]. We recently reported the potential palliative impacts of PO on psychological conditions such as apathy and depression in healthy Japanese adults [15]. These studies suggest that LNA has protective effects against age-associated cognitive and mental deterioration in the older adults. However, detailed reports of the impacts of PO on cognitive ability and mental condition in the elderly are lacking. Therefore, this study aimed to investigate the impacts of PO rich in LNA on cognitive function and mental health in elderly Japanese individuals.

2. Materials and Methods

2.1. Subjects

This 12-month, single-blinded, randomized, parallel-armed study was conducted among 64–84-year-old healthy elderly individuals living in Shimane Prefecture, Japan. All participants underwent a medical examination including anthropometry, a blood biochemical assessment, and cognitive-function and mental-health tests. Participants having respiratory, hepatic, renal, or cardiac disease; those having diabetes mellitus; those with endocrine, metabolic, or hematological diseases; those using any psychotropic drug/supplement that might significantly affect the results of the study; and those who had an allergy or hypersensitivity were excluded.

This study was performed following the principles of the Declaration of Helsinki and Good Clinical Practice, and the protocol was approved by the Shimane University Ethics Committee (Study No.: 1889, 2128). Written informed consent was obtained from all participants prior to participation. This interventional study was conducted during the period between 2015 and 2017. Participants were inquired to answer a self-reported general lifestyle questionnaire, which included questions related to their medical/medication history.

The participants were assigned to two groups: the control group (n = 33) and the PO group (n = 42). Participants in the control group received 7.0 mL of canola oil (The Nisshin OilliO Group, Ltd., Tokyo, Japan) daily, and those in the PO group received 7.0 mL of PO (O-san farm Co., Kawamoto, Shimane, Japan) daily for 12 months. The fatty acid profiles of the canola oil and PO are shown in Table 1.
Table 1. Basic fatty acid component of canola oil and perilla seed oil.

| Fatty Acids (g/100 g)      | Canola Oil | Perilla Seed Oil |
|---------------------------|------------|------------------|
| Palmitic acid (C16:0)     | 4.3        | 5.6              |
| Stearic acid (C18:0)      | 2.09       | 1.7              |
| Oleic acid (C16:0, ω-9)   | 61.7       | 13               |
| Linoleic acid (C18:2, ω-6) | 19        | 13.9             |
| α-linolenic acid (C18:3, ω-3) | 9.14      | 62.2             |

Perilla seed oil (PO) also contains vitamin E (67.8 mg/100 g). Data on canola oil were obtained from the United States Department of Agriculture (USDA) (https://fdc.nal.usda.gov/fdc-app.html#/food-details/1103863/nutrients, accessed on 14 January, 2017), and data on PO were obtained from Japan Food Research Laboratories (JFRL).

2.2. Anthropometry, Body Composition, and Dietary Intake Analysis

Body weight, height, and abdominal circumference of all participants were measured. Body composition was evaluated by a bioelectrical impedance analyzer WB-150 (TANITA Co., Tokyo, Japan). To evaluate the effects of PO intake on health status and lifestyle during the trial, the participants were asked to respond to a general questionnaire that included questions on medical/medication history and their lifestyle.

Dietary intake before and after the interventional study was estimated by a validated, brief-type self-administered diet history questionnaire (BDHQ) for the Japanese elderly [16]. The BDHQ is a four-page questionnaire with fixed portion sizes that inquires about the consumption frequency of selected foods to estimate the dietary intake of 58 food and beverage items in the previous month. The food and beverage items registered on the BDHQ were foods frequently consumed in Japan, mainly selected from a food list used in the National Health and Nutrition Survey of Japan. Based on the participant’s response to the BDHQ, the ad hoc computer algorithm assessed the amount of 98 nutritional factors intake during the previous month.

2.3. Blood Sampling

At baseline and after 3, 6, and 12 months of the trial, blood samples were collected either in the morning or afternoon, after ascertaining that the participants had not eaten breakfast or lunch, respectively. Then, blood samples were separated into serum and erythrocyte (red blood cell (RBC)) aliquots. RBC samples were stored at −80 °C within 8 h of collection until use. RBC samples were collected to monitor the fatty acid profile of the RBC plasma membranes (RBC-PM). Fresh serum samples were used to measure blood biochemistry and biological antioxidant potential (BAP) levels. The remaining serum samples were stored at −80 °C within 8 h of collection to measure serum brain-derived neurotropic factor (BDNF) levels.

2.4. Evaluation of Cognitive Functions and Mental Health

Cognitive functions were evaluated by the Hasegawa’s Dementia Scale-Revised (HDS-R) [17], Mini-Mental State Examination (MMSE) [18], and Frontal Assessment Battery (FAB) [19]. Apathy was measured using the Japanese version of the apathy scale [20]. Depression was assessed using the Zung Self-Rating Depression Scale (SDS) [21].

2.5. Blood Biochemical Analysis, Fatty Acid Profile, and Apolipoprotein E Genotyping

Biochemical analyses included evaluation of the levels of gamma-glutamyl transpeptidase, alanine aminotransferase, aspartate aminotransferase, albumin, total cholesterol, blood urea nitrogen, triglycerides, creatinine, blood sugar, and high- and low-density lipoprotein cholesterol using an automatic analyzer BiOLis 24i (Tokyo Boeki Medical System, Tokyo, Japan). In addition, hemoglobin A1c was determined by a commercially available kit (TFB Inc., Tokyo, Japan).

Serum BDNF level was quantified using a BDNF Emax ImmunoAssay System kit (Promega Inc., Madison, WI, USA) according to the company’s protocol.
Serum BAP level was determined using a free radical elective evaluator (FREE Carpe Diem) that included a spectrophotometric device reader, and measurement kits (BAP test; Wismerrl Co. Ltd., Tokyo, Japan) were optimized to the FREE Carpe Diem System according to the manufacturer’s protocol.

The fatty acid profile in the RBC-PM was measured by direct transmethylation as previously described [5,22].

Apolipoprotein E (APOE) genotyping was performed as previously described [7]. APOE single nucleotide polymorphism genotyping was performed by a real-time polymerase chain reaction (7900HT; Applied Biosystems, Waltham, MA, USA) using the TaqMan single nucleotide polymorphism genotyping assay for rs429358 and rs7412 with identification numbers G_3084793-20 and C_904973-10, respectively (Applied Biosystems Waltham, MA, USA).

2.6. Statistical Analysis

The Shapiro–Wilk test was carried out to evaluate the distribution of the data. Data are expressed as the mean ± SE. Changes in FAB (ΔFAB) and apathy (ΔApathy) scores and participants’ parameters at baseline and after 12 months of intervention were analyzed using the Mann–Whitney U test. LNA, EPA, and DHA levels in the RBC-PM, fatty acid profile of the RBC-PM, and serum BAP and BDNF levels were analyzed using repeated measures analysis of variance (ANOVA) followed by Bonferroni’s post hoc test. The correlations between FAB scores and BAP, and between ΔBAP and ΔApathy scores were evaluated using the Pearson’s correlation coefficient. All analyses were performed using the PASW Statistics software (version 23.0, SPSS Inc., Chicago, IL, USA). All statistical tests were two-tailed, and significance was set at p < 0.05.

3. Results

3.1. Demographic and Clinical Characteristics of Participants and Assessment of Dietary Intake

Seventy-five participants (40 women and 35 men) were randomly allocated to either the control group or the PO group. Baseline characteristics are shown in Table 2. Serum albumin levels were significantly greater in the PO group compared to the control group. Blood sugar and HbA1c levels were significantly lower in the PO group in comparison to the control group. The remaining parameters showed no significant differences between the two groups (Table 2).

Table 2. Participants’ baseline parameters.

|                     | Control (n = 33) | PO (n = 42) | Mean | Median | Min | Max | Mean | Median | Min | Max | p Value |
|---------------------|-----------------|-------------|------|--------|-----|-----|------|--------|-----|-----|---------|
| **Anthropometry**   |                 |             |      |        |     |     |      |        |     |     |         |
| Sex (male/female)   | 16/17           | 19/23       |      |        |     |     |      |        |     |     | 0.988   |
| Age (years)         | 71.0            | 71.3        | 64   | 84     | 71.0| 70.5| 65   | 83     |     |     | 0.776   |
| Height (cm)         | 155.3           | 153.8       | 137.0| 137.0  | 173.3|155.9|155.3|136.0  |175.0| 0.641|
| Body Weight (kg)    | 55.5            | 58.3        | 34.6 | 75.1   | 54.9 | 53.5|36.5 |80.8   |     |     | 0.818   |
| BMI (kg/m²)         | 22.9            | 22.4        | 15.4 | 28.6   | 22.4 | 22.3|16.9 |32.5   |     |     | 0.641   |
| BC (cm)             | 84.4            | 84.6        | 64.0 | 100.0  | 82.5 | 82.0|63.0 |116.0  |     |     | 0.409   |
| Body fat (%)        | 26.5            | 26.2        | 10.9 | 38.5   | 26.5 | 25.3|16.8 |36.3   |     |     | 0.993   |
| **Blood pressure**  |                 |             |      |        |     |     |      |        |     |     |         |
| SBP (mmHg)          | 148.1           | 147.0       | 116.0|198.0   |148.1|147.0|106.0|198.0  |     |     | 0.995   |
| DBP (mmHg)          | 81.3            | 81.0        | 57.0 | 102.0  | 84.1 | 83.0|49.0 |107.0  |     |     | 0.312   |
| **Cognitive index** |                 |             |      |        |     |     |      |        |     |     |         |
| HDS-R score         | 28.1            | 29.0        | 22.0 | 30.0   | 27.8 | 28.0|18.0 |30.0   |     |     | 0.503   |
| MMSE score          | 28.4            | 29.0        | 24.0 | 30.0   | 28.3 | 29.0|22.0 |30.0   |     |     | 0.412   |
| FAB score           | 15.7            | 16.0        | 11.0 | 18.0   | 15.5 | 16.0|8.0  |18.0   |     |     | 0.507   |
### Table 2. Cont.

|                                | Control (n = 33) | PO (n = 42) |
|--------------------------------|------------------|-------------|
|                                | Mean | Median | Min | Max | Mean | Median | Min | Max | p Value |
| **Emotional index**            |      |        |     |     |      |        |     |     |         |
| SDS score (32.6)               | 32.6 | 31.0   | 20.0| 49.0| 32.9 | 31.5   | 22.0| 52.0| 0.869   |
| Apathy score (10.3)            | 10.3 | 11.0   | 1.0 | 24.0| 10.3 | 10.0   | 2.0 | 23.0| 0.981   |
| **Blood biochemistry**         |      |        |     |     |      |        |     |     |         |
| GOT (U/L) (25.6)               | 25.6 | 25.0   | 17.0| 43.0| 26.1 | 26.0   | 16.0| 40.0| 0.695   |
| GPT (U/L) (22.6)               | 22.6 | 19.0   | 8.0 | 64.0| 21.0 | 19.0   | 12.0| 39.0| 0.465   |
| γ-GT (IU/L) (39.7)             | 39.7 | 22.0   | 11.0| 365.0| 4.9 | 26.0   | 23.0| 8.1 | 0.787   |
| ALB (g/dL) (4.3)               | 4.3  | 4.3    | 3.4 | 4.9 | 4.4  | 4.4    | 4.1 | 5.1 | 0.002   |
| TC (mg/dL) (208.0)             | 208.0| 207.0  | 161.0| 296.0| 215.8| 215.0  | 144.0| 294.0| 0.305   |
| TG (mg/dL) (112.7)             | 112.7| 98.0   | 53.0| 255.0| 118.6| 108.0  | 50.0 | 308.0| 0.636   |
| BUN (mg/dL) (16.0)             | 16.0 | 15.0   | 9.5 | 26.1| 15.9 | 15.2   | 10.4 | 35.7| 0.867   |
| CRE (mg/dL) (0.7)              | 0.7  | 0.7    | 0.5 | 1.5 | 0.7  | 0.7    | 0.5 | 1.6 | 0.824   |
| BS (mg/dL) (113.8)             | 113.8| 99.0   | 84.0| 252.0| 97.2 | 94.0   | 69.0 | 191.0| 0.018   |
| HDL-C (mg/dL) (60.5)           | 60.5 | 59.0   | 32.0| 99.0| 65.7 | 62.0   | 40.0 | 113.0| 0.202   |
| LDL-C (mg/dL) (124.9)          | 124.9| 112.0  | 68.0| 210.0| 126.2| 129.0  | 73.0 | 184.0| 0.838   |
| HbA1c (NGSP) (%) (6.2)         | 6.2  | 5.9    | 5.2 | 10.7| 5.7  | 5.6    | 5.2 | 6.8 | 0.004   |

ALB: albumin; BC: body circumference; BMI: body mass index; BUN: blood urea nitrogen; BS: blood sugar; CRE: creatinine; DBP: diastolic blood pressure; FAB: Frontal Assessment Battery score; GPT: glutamate-pyruvate transaminase; GOT: glutamate-oxaloacetate transaminase; γ-GT: γ-glutamyl transpeptidase; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; HDS-R: Hasegawa’s dementia scale-revised; LDL-C: low density lipoprotein cholesterol; MMSE: Mini-Mental State Examination; NGSP: National glycohemoglobin standardization program; n: number; PO: perilla seed oil-intake group; SBP: systolic blood pressure; SDS: self-rating depression scale; TC: total cholesterol; TG: triglyceride; Min: minimum value; Max: maximum value. p-value: control vs. PO.

The frequency of different APOE alleles was measured in both the groups. The frequency of the APOE2/2 or APOE2/3 genotype was 21 (70.0%) in the control group and 31 (77.5%) in the PO group. The frequency of the APOE2/4 or APOE3/4 genotype was 8 (26.7%) in the control group and 7 (17.5%) in the PO group. The frequency of the APOE4/4 genotype was 1 (3.3%) in the control group and 2 (5.0%) in the PO group. These results indicate that there were no significant differences in the distribution of different APOE alleles between the two groups.

The 12-month study was completed by 24 control group subjects and 35 PO group subjects (Figure 1). Data acquired from the general questionnaire on lifestyle habits and medical/medication history at baseline and after 12 months of intervention showed no differences. There were no noticeable side effects (allergic reaction, palpitations, stomach irritation, etc.) that affected the daily lives of the participants that were noted in either group.

No significant differences between the two groups in dietary intake based on responses to the BDHQ at either baseline or after 12 months were found (Table 3), indicating that PO intake for 12 months did not affect the dietary intake and nutritional values.

Participant characteristics after 12 months of intervention are shown in Table 4. Serum HbA1c levels were significantly lower in the PO group compared to the control group. The remaining parameters showed no significant differences between the two groups (Table 4). The mean changes (Δ) in the anthropometry, blood pressure, and blood biochemical parameters including serum albumin, blood sugar, and HbA1c after 12 months of intervention were not significantly different between the two groups (data not shown), indicating that PO intake did not influence the renal function, hepatic function, or lipid metabolism.
Table 3. Dietary intake evaluated by the BDHQ before and after intervention in the control and *perilla* seed oil-intake groups.

|                       | Baseline   | Month 12 | Month 12—Baseline |
|-----------------------|------------|----------|-------------------|
|                       | Control (n = 33) | PO (n = 42) | Control (n = 24) | PO (n = 35) | Control (n = 24) | PO (n = 35) | p-Value |
| Energy (KJ/d)         | 8774 ± 565 | 9302 ± 493 | 8326 ± 454       | 8560 ± 1905 | −448 ± 473       | −742 ± 371 | 0.670   |
| Protein (g/d)         | 84.4 ± 4.8 | 92.0 ± 6.4 | 79.6 ± 5.6       | 83.6 ± 5.3  | −4.7 ± 5.9       | −8.4 ± 3.5 | 0.452   |
| Fat (g/d)             | 63.9 ± 4.3 | 65.2 ± 4.6 | 58.5 ± 4.2       | 58.1 ± 3.9  | −5.4 ± 3.7       | −7.1 ± 2.8 | 0.704   |
| Carbohydrate (g/d)    | 277.3 ± 22.5 | 279.9 ± 15.4 | 266.9 ± 15.9 | 262.9 ± 14.8 | −10.4 ± 18.5      | −17.0 ± 14.7 | 0.779   |
| Total dietary fiber (g/d) | 15.0 ± 1.1 | 15.6 ± 1.0  | 14.8 ± 1.3       | 15.7 ± 1.1  | −0.2 ± 1.3       | 0.1 ± 0.9  | 0.842   |
| Saturated fat (g/d)   | 22.3 ± 1.3 | 17.8 ± 1.3  | 15.3 ± 1.2       | 15.3 ± 1.1  | −2.0 ± 1.0       | −2.5 ± 0.8 | 0.713   |
| Monounsaturated fat (g/d) | 15.4 ± 1.6 | 22.8 ± 1.7  | 20.7 ± 1.6       | 20.5 ± 1.5  | −1.6 ± 1.4       | −2.3 ± 1.1 | 0.668   |
| Polyunsaturated fat (g/d) | 15.0 ± 0.9 | 15.4 ± 1.1  | 14.2 ± 1.0       | 13.9 ± 0.9  | −0.7 ± 0.9       | −1.4 ± 0.7 | 0.524   |
| ω-6 polyunsaturated fat (g/d) | 11.8 ± 0.7  | 11.6 ± 0.8  | 11.5 ± 0.8      | 10.6 ± 0.7  | −0.4 ± 0.6       | −1.0 ± 0.5 | 0.507   |
| ω-3 polyunsaturated fat (g/d) | 3.5 ± 0.3  | 3.7 ± 0.3   | 3.2 ± 0.2        | 3.3 ± 0.2   | −0.3 ± 0.3       | −0.5 ± 0.2 | 0.667   |
| LNA (C18:3ω-3) (g/d)  | 1.84 ± 0.12 | 1.82 ± 0.13 | 1.84 ± 0.14      | 1.69 ± 0.12 | 0.005 ± 0.1      | −0.13 ± 0.09 | 0.353   |
| EPA (C20:5ω-3) (g/d)  | 0.51 ± 0.06 | 0.59 ± 0.06 | 0.41 ± 0.04      | 0.48 ± 0.04 | −0.098 ± 0.06    | −0.11 ± 0.05 | 0.919   |
| DHA (C22:6ω-3) (g/d)  | 0.84 ± 0.09 | 0.96 ± 0.10 | 0.68 ± 0.06      | 0.74 ± 0.06 | −0.16 ± 0.10     | −0.16 ± 0.07 | 0.976   |

Values are means ± SE. BDHQ: brief-type self-administered diet history questionnaire; d, day; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LNA α-Linolenic acid; PO: *perilla* seed oil-intake group. p-value: control vs. PO.

Table 4. Participants’ parameters after 12 months intervention.

|                       | Control (n = 24) | PO (n = 35) |
|-----------------------|-----------------|-------------|
| **Anthropometry**     | Mean | Median | Min | Max | Mean | Median | Min | Max | p-Value |
| Sex (male/female)     | 12/12 | 71.3   | 65  | 85  | 16/19 | 72.0   | 70.8 | 66  | 84  | 0.883   |
| Age (years)           | 72.0  | 154.6  | 136.0 | 170.5 | 156.3 | 155.7 | 136.4 | 175.0 | 81.0 | 0.512   |
| Height (cm)           | 55.9  | 23.3   | 17.5 | 29.8 | 22.1  | 21.7  | 16.3  | 32.1  | 0.100   |
| Body Weigh (kg)       | 85.7  | 86.5   | 65.5 | 103.0 | 82.0  | 82.6  | 63.0  | 115.0 | 0.103   |
| Body fat (%)          | 26.1  | 25.4   | 6.7  | 41.4 | 25.4  | 24.4  | 14.6  | 42.2  | 0.578   |

| **Blood pressure**    | Mean | Median | Min | Max | Mean | Median | Min | Max | p-Value |
|-----------------------|------|--------|-----|-----|------|--------|-----|-----|---------|
| SBP (mmHg)            | 134.3| 136.0  | 104.0| 188.0| 135.7| 139.0  | 99.0 | 174.0| 0.396   |
| DBP (mmHg)            | 79.3 | 76.0   | 56.0 | 106.0| 76.5 | 76.3   | 55.0 | 99.0 | 0.552   |

| **Cognitive index**   | Mean | Median | Min | Max | Mean | Median | Min | Max | p-Value |
|-----------------------|------|--------|-----|-----|------|--------|-----|-----|---------|
| HDS-R score           | 28.7 | 28.8   | 26.0 | 30.0 | 29.1 | 29.3   | 26.0 | 30.0 | 0.194   |
| MMSE score            | 29.0 | 29.0   | 25.0 | 30.0 | 29.2 | 29.4   | 26.0 | 30.0 | 0.865   |
| FAB score             | 16.0 | 16.2   | 12.0 | 18.0 | 16.5 | 16.8   | 13.0 | 18.0 | 0.223   |
### Table 4. Cont.

| Control (n = 24) | PO (n = 35) |
|-----------------|-------------|
| **Mean**        | **Median**  | **Min** | **Max** | **Mean** | **Median** | **Min** | **Max** | **p-Value** |
| **Emotional index** |             |         |         |         |             |         |         |         |
| SDS score       | 32.3        | 30.3    | 21.0    | 54.0    | 31.9        | 31.0    | 22.0    | 51.0    | 0.547       |
| Apathy score    | 9.5         | 9.0     | 0.0     | 19.0    | 8.4         | 8.1     | 0.0     | 26.0    | 0.383       |
| **Blood biochemistry** |         |         |         |         |             |         |         |         |
| GOT (U/L)       | 24.7        | 24.3    | 18.0    | 46.0    | 26.1        | 24.0    | 16.0    | 60.0    | 0.792       |
| GPT (U/L)       | 19.2        | 16.3    | 11.0    | 46.0    | 20.1        | 17.7    | 10.0    | 53.0    | 0.501       |
| γ-GT (IU/L)     | 31.6        | 19.3    | 13.0    | 172.0   | 29.6        | 23.5    | 11.0    | 102.0   | 0.677       |
| ALB (g/dL)      | 4.2         | 4.2     | 3.4     | 4.6     | 4.3         | 4.3     | 3.9     | 4.9     | 0.134       |
| TC (mg/dL)      | 196.0       | 196.0   | 124.0   | 255.0   | 205.1       | 202.0   | 144.0   | 279.0   | 0.342       |
| TG (mg/dL)      | 105.1       | 91.0    | 51.0    | 264.0   | 108.1       | 82.0    | 41.0    | 402.0   | 0.605       |
| BUN (mg/dL)     | 16.5        | 15.7    | 11.3    | 24.5    | 16.6        | 16.0    | 9.8     | 23.6    | 0.896       |
| CRE (mg/dL)     | 0.8         | 0.7     | 0.5     | 1.9     | 0.8         | 0.7     | 0.5     | 1.5     | 0.694       |
| BS (mg/dL)      | 105.7       | 98.0    | 88.0    | 166.0   | 100.9       | 97.3    | 73.0    | 216.0   | 0.290       |
| HDL-C (mg/dL)   | 57.4        | 56.3    | 31.0    | 80.0    | 64.9        | 64.3    | 40.0    | 94.0    | 0.068       |
| LDL-C (mg/dL)   | 117.9       | 112.5   | 70.0    | 167.0   | 119.3       | 124.0   | 49.0    | 191.0   | 0.796       |
| HbA1c (NGSP) (%)| 6.2         | 6.0     | 5.3     | 7.9     | 5.8         | 5.7     | 5.2     | 6.9     | 0.020       |

ALB: albumin; BC: belly circumference; BMI: body mass index; BUN: blood urea nitrogen; BS: blood sugar; CRE: creatinine; DBP: diastolic blood pressure; FAB: Frontal Assessment Battery score; GPT: glutamate-pyruvate transaminase; GOT: glutamate-oxaloacetate transaminase; γ-GT: gamma-glutamyl transpeptidase; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; HDS-R: Hasegawa’s dementia scale-revised; LDL-C: low density lipoprotein cholesterol; Max: maximum value; Min: minimum value; MMSE: Mini-Mental State Examination; NGSP: National glycohemoglobin standardization program; n: number; PO: *perilla* seed oil-intake group; SBP: systolic blood pressure; SDS: self-rating depression scale; TC: total cholesterol; TG: triglyceride; p-value: control vs. PO.

### 3.2. Cognitive Functions and Mental Health Assessment

The mean HDS-R, MMSE, and FAB scores of all participants (n = 75) at baseline were 27.9 ± 0.3/30, 28.3 ± 0.2/30, and 15.6 ± 0.2/18, respectively (Table 2). At baseline and after 12 months of intervention, after adjustment for serum albumin, blood sugar, and HbA1c, the total scores were not different between the two groups (Tables 2 and 4). However, the mean change (Δ) in the FAB scores from baseline to month 12 was only slightly higher (p = 0.094) in the PO group than in the control group (Figure 2A).

**Figure 2.** Effect of PO-intake on FAB and apathy scores. Mean changes (Δ) in the FAB scores (A) and apathy scores (B) after 12 months of intervention in the PO and control groups. Bar represents mean ± SE. PO, *perilla* seed oil; FAB, Frontal Assessment Battery.

At baseline and after 12 months, there were no significant differences in the apathy and SDS scores between the two study groups (Tables 2 and 4). However, the mean change (Δ) in the apathy scores from baseline to month 12 tended to be lower in the PO group compared to the control group (p = 0.100, Figure 2B).
3.3. Fatty Acid Profile of the RBC-PM

The RBC-PM fatty acid profiles at baseline and after 12 months are indicated in Table 5. LNA levels markedly increased over time in the PO group; the other RBC-PM fatty acid levels did not alter. The RBC-PM fatty acid profile remained unchanged over time in the control group. This increase in the mean LNA levels of the RBC-PM further supported the consumption compliance in the PO group subjects.

Table 5. Fatty acid profile of the red-blood cell plasma membranes at baseline and after 12 months of intervention.

| Fatty acid (mol%) | Baseline | 12-Months |
|-------------------|----------|-----------|
|                   | Control (n = 33) | PO (n = 42) | Control (n = 24) | PO (n = 35) | p-Value |
| PLA               | 25.8 ± 0.2 | 25.6 ± 0.2 | 23.6 ± 0.5 | 24.0 ± 0.4 | 0.557 |
| POA               | 0.4 ± 0.0  | 0.4 ± 0.0  | 0.5 ± 0.1  | 0.5 ± 0.0  | 0.591 |
| STA               | 17.8 ± 0.2 | 17.7 ± 0.2 | 17.5 ± 0.3 | 18.0 ± 0.3 | 0.284 |
| OLA               | 14.7 ± 0.5 | 14.6 ± 0.5 | 15.8 ± 0.3 | 15.9 ± 0.3 | 0.430 |
| LLA               | 11.3 ± 0.3 | 11.6 ± 0.3 | 11.7 ± 0.3 | 11.7 ± 0.5 | 0.965 |
| LNA               | 0.2 ± 0.0  | 0.2 ± 0.0  | 0.2 ± 0.0  | 0.4 ± 0.0  | <0.0001 |
| AA                | 10.5 ± 0.3 | 11.0 ± 0.3 | 10.8 ± 0.5 | 10.3 ± 0.5 | 0.513 |
| EPA               | 2.1 ± 0.2  | 2.0 ± 0.1  | 2.1 ± 0.2  | 2.1 ± 0.1  | 0.774 |
| DPA               | 2.0 ± 0.1  | 2.0 ± 0.0  | 1.5 ± 0.1  | 1.5 ± 0.1  | 0.681 |
| C24:0             | 3.7 ± 0.1  | 3.6 ± 0.1  | 4.7 ± 0.1  | 4.8 ± 0.1  | 0.702 |
| DHA               | 7.5 ± 0.2  | 7.6 ± 0.2  | 7.6 ± 0.4  | 7.0 ± 0.4  | 0.295 |
| C24:1             | 3.8 ± 0.1  | 3.7 ± 0.1  | 3.9 ± 0.1  | 3.8 ± 0.1  | 0.587 |

Values are mean ± SE. AA: arachidonic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid; EPA: eicosapentaenoic acid; LLA: linoleic acid; LNA: α-linolenic acid; n: number; OLA: oleic acid; PLA: palmitic acid; PO: perilla seed oil-intake group; STA: stearic acid. p-value is control vs. PO.

LNA, EPA, and DHA levels in the RBC-PM assessed at baseline and at 3, 6, and 12 months after the treatment are shown in Figure 3. LNA levels increased significantly at 3, 6, and 12 months in the PO group (Figure 3A). Further, compared to the control group, LNA levels were significantly higher in the PO group at all time points (F = 11.307, p < 0.0001). EPA (Figure 3B, F = 0.152, p = 0.929) and DHA (Figure 3C, F = 0.067, p = 0.523) levels in the RBC-PM remained unchanged during the intervention and showed no significant difference between the two groups at all time points.

Figure 3. Effect of dietary PO on fatty acid levels in the RBC-PM of the PO-intake and control groups. (A) LNA, (B) EPA, and (C) DHA levels at 3, 6, and 12 months after intervention. Control group, n = 24–33; PO group, n = 35–42. Results are mean ± SE. * p < 0.05. LNA, linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PO, perilla seed oil-intake group; RBC-PM, red blood cell plasma membranes.
3.4. Biological Antioxidant Potential (BAP) and Brain Derived Neurotropic Factor (BDNF) Levels

At baseline, there were no significant differences in serum BAP and BDNF levels between the two groups. At 12 months, serum BAP levels were significantly greater in the PO group compared to the control group (Figure 4A). Serum BDNF levels showed no difference between the two groups at baseline and at 12 months after the trial (Figure 4B).

![Figure 4](image) Effect of dietary PO on serum BAP (A) and BDNF levels (B) in the PO-intake and control groups. Values are mean ± SE. * p < 0.05, compared with the control value. Control group, n = 24–33; PO group, n = 35–42. BAP, biological antioxidant potential; BDNF, brain-derived neurotrophic factor; PO, *perilla* seed oil-intake group.

Serum BAP levels were positively correlated (p = 0.032) with FAB scores at baseline after adjustment for serum albumin, blood sugar, and HbA1c (Figure 5). For all participants, the change (Δ) in the serum BAP from baseline to month 12 tended to be negatively correlated (p = 0.096) with the change (Δ) in apathy scores from baseline to month 12 after adjustment for serum albumin, blood sugar, and HbA1c (Figure 6).

![Figure 5](image) Scatter plot of the relationship between FAB scores and serum BAP at baseline. (Open circle) control group; (Grey circle) *perilla* seed oil-intake group. FAB, Frontal Assessment Battery; BAP, biological antioxidant potential.
Figure 6. Scatter plot of the relationship between changes in apathy scores and changes in serum BAP from baseline to month 12. (Open circle) control group; (Grey circle) perilla seed oil-intake group. BAP, biological antioxidant potential.

4. Discussion

Our results suggest that daily dietary PO supplementation increases blood LNA levels and BAP and helps in maintaining optimal cognitive function and good mental health in Japanese elderly individuals with age-related cognitive decline. Further, our study also suggests that dietary PO intake is not associated with any clinically significant side effects. It has been shown that the natural ingredients of the PO are nontoxic [23]. To the best of our knowledge, this is the first long-term (12 months), randomized, controlled trial to evaluate the influence of PO intake on cognitive functions and mental health in 64–84-year-old healthy Japanese individuals with age-related cognitive decline. All the participants were in excellent compliance during the study period, as the RBC-PM LNA levels were significantly greater in the PO group compared to the control group at 12 months (Table 2).

LNA, an essential PUFA, possesses pharmacological activities, including anti-cardiovascular, antioxidant, and neuroprotective activities [24–26]. In our study, the change in the mean FAB score after 12 months of intervention was only slightly higher in the PO group than in the control group (p = 0.094) (Figure 2A), suggesting a possible protective effects of the PO diet against age-related cognitive decline in the elderly. Contrary to our results, Kamalashiran et al. [27] reported that the use of PO along with standard neuroprotective therapy in patients with mild to moderate dementia does not improve cognitive function. The discrepancy between our results and those reported by Kamalashiran et al. might be because of differences in the study participants and PO dose. Kamalashiran et al. targeted patients with an MMSE score of 10–23, and the PO dose was 3 g/day, while we targeted healthy elderly individuals with an MMSE score of 25 or higher, and the PO dose used in our study was 7 g/day.

The brain is sensitive to oxidative balance, and oxidative stress is involved in the initiation and progression of cognitive impairment. It has been shown that cognitive impairment is significantly associated with oxidative stress, and enhancing the antioxidant system may protect cognitive ability in the elderly [1]. We observed that after 12 months of intervention, serum BAP levels were significantly greater in the PO group compared to those in the control group (Figure 4). Serum BAP, which reflects the total antioxidant
capacity, is a generally used biomarker of oxidative stress and can be easily measured in large populations [28]. In our study, serum BAP levels were positively correlated with the FAB score at baseline (Figure 5), suggesting that dietary antioxidants may protect against age-related cognitive decline in the elderly. This observation corresponds with a previous report by Pesce et al. [29] that showed that improvements in memory and global cognitive function were significantly related with increased resistance to oxidative stress at the plasma level in healthy elderly people. Vitamin C, vitamin E, and polyphenols are well-known antioxidants [30]. PO contains vitamin E (Table 1) and other antioxidants [31], which might have contributed to the increased serum BAP in the PO-administered participants. Taken together, the positive effects of PO intake on age-associated cognitive decline in healthy elderly individuals may be related to its antioxidant activity, causing increased resistance against oxidative stress.

Lee et al. [14] showed that, in rats, ameliorated spatial learning and memory upon supplementation of a LNA-rich perilla diet is correlated with the differential expression of hippocampal proteins. Functional annotation revealed that these differentially expressed proteins are involved in several important functions, including regulation of the cytoskeleton, energy metabolism, transport, neurogenesis, and apoptosis. This suggests that dietary LNA supplementation induces changes in the membrane fatty acid composition, leading to improved cognitive function. Moreover, the beneficial effects of LNA on learning and memory in an Aβ25-35-infused AD murine model are comparable to those exerted by DHA [32]. In rodents, ingestion of ω-3 PUFA including LNA increases the DHA and EPA levels in the hippocampus, leading to beneficial effects on brain functions [33]. PO mediates neuroprotection via its antioxidative actions against dementia, as PO is rich in LNA [34]. However, the metabolic conversion of LNA to ω-3 PUFA, particularly DHA, in humans is very limited [9,35]. Normally, an increase in the levels of dietary components in the RBC-PM reflects their incorporation into the cell membranes of other tissues. Therefore, their increased levels could be contributing to several physiological activities, including brain function. In the present study, LNA intake did not change the DHA and EPA levels in the RBC-PM of the elderly (Figure 3B,C). Therefore, it is not clear from our results whether the protective action of a PO diet against age-related cognitive decline in the elderly is the effect of LNA alone or the combined effect of LNA with DHA and/or EPA. LNA can be easily oxidized and is a preferred substrate for ketogenesis [36]. Freemantle et al. [37] suggested that LNA could induce mild ketonemia aimed at retaining or restoring cognitive function in the elderly, and that the use of LNA as a mildly ketogenic fatty acid might improve neuronal function. Altogether, these findings suggest that the protective action of the PO diet against age-correlated cognitive decline in the elderly is a direct effect of LNA. However, further studies are required to support our observation.

Apathy scores are a measure of motivational engagement [19], while SDS scores reflect the degree of depression [20]. The symptoms of motivational engagement and depression usually overlap. The relevance between the brain lipids and mental function remains unclear. In the present study, the mean changes in apathy scores after 12 months of intervention tended to be larger in the PO group than that of the control group (p = 0.100) (Figure 2B), suggesting an improvement in apathy. This result is consistent with that of our recent study in healthy Japanese adults that showed the potential palliative effects of PO on mental conditions such as depression and apathy [15]. Apathy reduces the quality of life in the elderly and in patients with neurological disorders such as dementia and AD. Su et al. [38] has shown that ω-3 fatty acids have mood-regulating and antidepressant effects in humans. We previously reported that long-term supplementation of dietary ω-3 PUFA-enriched meals improves apathy in elderly Japanese individuals with cognitive impairment [7]. In this study, serum BAP was found to be negatively correlated with apathy scores (p = 0.032, Figure 5), suggesting that antioxidants supplementation could reduce apathy in the elderly. Taken together, our results showed that PO intake improves apathy in both adults and the elderly, presumably by reducing oxidative stress.
Although studies showed an association between serum BDNF levels and cognitive functions [39,40], results have been inconsistent. Hakansson et al. [41] reported that the capability to respond to physical exercise with increased serum BDNF concentration is correlated with cognitive function, and the ability to produce peripheral BDNF is a marker of BDNF availability in the brain. Moreover, administration of ω-3 PUFA increases serum BDNF levels in Aβ-infused AD model rats [42] and during the first episode of schizophrenia [43]. The relationship between ω-3 PUFA intake and increased serum BDNF may contribute to the effectiveness of ω-3 PUFA on cognitive function. These results suggest that dietary PO administration may influence serum BDNF levels in elderly individuals with age-related cognitive decline. In our study, however, PO intake had no effect on serum BDNF levels in healthy elderly individuals (Figure 4).

In the present study, compared to baseline, the LNA levels in the RBC-PM after 3, 6, and 12 months of trial were significantly increased in the PO group (Figure 3A). By contrast, the levels of EPA and DHA in the RBC-PM of the PO group did not alter during the trial (Figure 3B,C). Our results are consistent with those of Hamazaki et al. [44], who reported that PO intake does not influence EPA and DHA levels of the human plasma phospholipid fraction. Contrary to these results, we recently reported that in Japanese subjects, PO intake significantly increases both LNA and EPA levels in the RBC-PM after the intervention, but the DHA levels remain unaffected [15]. In both of our interventional studies, the amount of PO administered was the same (7.0 mL/day PO, which is equivalent to about 4 g LNA/day) for both adults and the elderly, yet the results were different. Studies showed that LNA is not converted to DHA in all cases [9,35], and there is a difference between adults and the elderly with respect to their abilities of converting LNA to DHA. The initial conversion of LNA to 18:4 ω-3 by the action of Δ6-desaturase is the rate-limiting reaction of the pathway in which LNA is metabolically converted to EPA and DHA. Burdge and Wootten [45] indicated that the conversion of LNA to EPA in women aged approximately 28 years was markedly greater (2.5-fold) than that in men of a similar age, suggesting a sex-associated difference in the activity of the desaturation-elongation pathway. Thus, the pathway might be regulated by sex hormones, particularly estrogen [46]. In the present study, however, this pathway appears to be less affected by sex hormones since the women participants were 64–84 years old, and thus, sex differences seem to be irrelevant. Studies showed that in mice, the levels of Δ6-desaturase in the liver decrease with age (40% decrease between 4 and 17 months of age) [47], suggesting that an age factor might be involved in LNA metabolism. Therefore, differences in the RBC-PM EPA levels might be due to the age difference of the subjects, although the clear mechanisms are unknown. Taken together, our results showed that LNA improves cognitive function and mental condition in the elderly without significantly increasing the brain EPA and DHA levels. Further studies are needed to understand the underlying molecular mechanism.

The APOE-ε4 allele has been consistently shown to be the strongest and most prevalent genetic risk factor for sporadic late-onset AD, and individuals carrying the APOE-ε4 allele have an increased risk of developing AD [48,49]. Because of the pleiotropic nature of APOE possession, the APOE-ε4 allele can have deleterious effects by influencing multiple biological processes, including lipid metabolism, amyloid beta deposition, neuro-inflammation, neurogenesis, and synaptic function [50,51]. This suggests that the penetrance of the APOE-ε4 allele influences the rate of cognitive dysfunction and the likelihood of transitioning to mild cognitive impairment (MCI) and AD, which is variable and potentially modifiable [52,53]. Therefore, since the difference in the APOE-ε4 allele frequency may affect the results of the present interventional study, it is meaningful to measure the allele frequency. In this study, there were no significant differences in the distribution of different APOE-ε4 alleles between the control and PO groups. Thus, it seems that the difference in frequency of APOE-ε4 alleles of participants did not affect the outcome in this interventional study.

In the present study, serum albumin, blood sugar, and HbA1c levels at baseline were significantly different between the control and PO groups (Table 2). Since participants in this study were randomly assigned into two groups at the baseline, not all outcomes may
be the same between the two groups. We are unsure whether these differing outcomes would affect the value of this study. Several epidemiological studies have reported that serum albumin [54] and HbA1c [55] are associated with cognitive decline in the elderly. Thus, these were analyzed as confounding factors when comparing the impacts of PO intake on cognitive ability between the control and PO groups. Additionally, we evaluated the changes (Δ) in these outcomes from baseline to month 12.

Our study has several limitations. First, since the subjects in this study were healthy elderly people without cognitive impairment and mental illness, the decline in their cognition and mental health parameters were mostly age-related, and, hence, there were no significant differences between the PO and control groups. Future studies are required to examine the impacts of dietary PO intake on subjects with cognitive impairment and mental illness including dementia and depression. Second, the sample size in our study was small with participants from a localized population, which limits the generalizability of our findings. Third, a total of 16 subjects (9 in the placebo group, 7 in the PO group) dropped out during the 12-month intervention period due to illness or personal reasons (Figure 1). As dropouts may have a significant impact on the composition of the sample and in turn the results, care should be taken in interpreting the results. Fourth, although the group assignment and the type of oil distributed were not disclosed to the subjects, they may have been able to distinguish the type of oil by taste and odor. Moreover, placebo effects may be included in behavioral measurements in this single-blind study. In the future, it may be necessary to conduct a double-blind study in a state where the taste and odor of oil cannot be distinguished, such as by using encapsulated oil. Fifth, we had no information on the genetic background of the participants and did not continue follow-up after the termination of the study.

5. Conclusions

Dietary PO intake increases serum LNA levels and BAP in healthy elderly Japanese individuals. Moreover, PO intake mitigates the age-related cognitive and mental decline in elderly individuals without any harmful side effects. These effects might be the result of increased antioxidant potential due to PO intake. Further studies are required to elucidate the mechanisms underlying the beneficial effects of PO on cognitive function and mental health.

Author Contributions: Conceptualization, M.H.; data curation, T.I. and H.W.; formal analysis, K.M. and Y.T.; funding acquisition, M.H. and T.I.; investigation, M.H., K.M., T.I., H.W., Y.T. and M.O.; methodology, M.H., K.M. and K.Y.; project administration, M.H. and K.Y.; resources, M.H., S.K., K.Y. and O.S.; software, M.H. and S.H.; supervision, M.H., S.H., S.K., K.Y. and O.S.; validation, M.H., K.M., S.K. and K.Y.; visualization, M.H., K.M., S.H. and H.W.; writing—original draft, M.H., K.M. and S.H.; writing—review and editing, M.H., K.M. and S.H. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a Ministry of Education, Culture, Sports, Science, and Technology of Japan Grant-in-Aid for Scientific Research (C) 26500008 (M.H.).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and Good Clinical Practice, and approved by the Shimane University Ethics Committee (Study No.: 1889, 2128, date of approval: 27 July 2015 and 22 February 2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available upon reasonable request from the corresponding author.

Acknowledgments: We sincerely thank the participants of the study. We thank O-san farm Co., (Kawamoto, Shimane, Japan) for their generous gift of PO.

Conflicts of Interest: The authors declare that they have no competing interests.
References

1. Akbaraly, N.T.; Faure, H.; Gourlet, V.; Favier, A.; Berr, C. Plasma carotenoid levels and cognitive performance in an elderly population: Results of the EVA Study. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62, 308–316. [CrossRef] [PubMed]

2. Liu, P.Y.; Chiu, C.C.; Huang, S.Y.; Su, K.P. A meta-analytic review of polysaturated fatty acid compositions in dementia. J. Clin. Psychiatry 2012, 73, 1245–1254. [CrossRef] [PubMed]

3. Hashimoto, M.; Maekawa, M.; Katakura, M.; Hamasaki, K.; Matsuoka, Y. Possibility of polysaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses. J. Pharmacol. Sci. 2014, 124, 294–300. [CrossRef]

4. Freund-Levi, Y.; Eriksdotter-Jönhagen, M.; Cederholm, T.; Basun, H.; Faxén-Irving, G.; Garland, A.; Vedin, I.; Vessby, B.; Wahlund, L.O.; Palmblad, J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch. Neurol. 2006, 63, 1402–1408. [CrossRef] [PubMed]

5. Hashimoto, M.; Yamashita, K.; Kato, S.; Tamai, T.; Tanabe, Y.; Mitarai, M.; Matsumoto, I.; Ohno, M. Beneficial effects of daily dietary omega-3 polysaturated fatty acid supplementation on age-related cognitive decline in elderly Japanese with very mild dementia: A 2-year randomized, double-blind, placebo-controlled trial. J. Aging Res. Clin. Pract. 2012, 1, 193–201.

6. Martí, A.; Fortique, F. Omega-3 fatty acids and cognitive decline: A systematic review. Nutr. Hosp. 2019, 36, 939–949.

7. Hashimoto, M.; Yamashita, K.; Kato, S.; Tamai, T.; Tanabe, Y.; Mitarai, M.; Matsumoto, I.; Ohno, M.; Yamaguchi, S.; Shido, O. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. Geriatr. Gerontol. Int. 2017, 17, 330–337. [CrossRef] [PubMed]

8. Ahmed, H.M. Ethnomedicinal, Phytochemical and Pharmacological Investigations of Perilla frutescens (L.) Britt. Molecules 2018, 24, 102. [CrossRef] [PubMed]

9. Burdge, G. Alpha-linolenic acid metabolism in men and women: Nutritional and biological implications. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 137–144. [CrossRef] [PubMed]

10. Campos, H.; Baylin, A.; Willett, W.C. α-Linolenic acid and risk of nonfatal acute myocardial infarction: Campos: α-Linolenic acid myocardial infarction. Circulation 2008, 118, 339–345. [CrossRef]

11. Albert, C.M.; Oh, K.; Whang, W.; Manson, J.E.; Chae, C.U.; Stampfer, M.J.; Willett, W.C.; Hu, F.B. Dietary α-linolenic acid intake and risk of sudden cardiac death and coronary heart disease. Circulation 2005, 112, 3232–3238. [CrossRef] [PubMed]

12. Zhao, G.; Etherton, T.D.; Martin, K.R.; Gillies, P.J.; West, S.G.; Kris-Etherton, P.M. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am. J. Clin. Nutr. 2007, 85, 385–391. [CrossRef] [PubMed]

13. Nguemeni, C.; Delplanque, B.; Rovere, C.; Simon-Rousseau, N.; Gandin, C.; Agnani, G.; Nahon, J.L.; Heurteaux, C.; Blondeau, N. Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol. Res. 2010, 61, 226–233. [CrossRef]

14. Lee, J.; Park, S.; Lee, J.Y.; Yeo, Y.K.; Kim, J.S.; Lim, J. Improved spatial learning and memory by perilla diet is correlated with immunoreactivities to neurofilament and neurofilament in hilus of dentate gyrus. Proteome Sci. 2012, 10, 1–12. [CrossRef] [PubMed]

15. Hashimoto, M.; Matsuzaki, K.; Kato, S.; Hossain, S.; Ohno, M.; Shido, O. Twelve-month Studies on Perilla frutescens L. Britt. feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: Possible role of neuronal mitochondria metabolism. J. Hong Kong Coll. Psychiatr. 1994, 20, 4–20. [PubMed]

16. Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for dementia. J. Psychiatr. Res. 1975, 12, 189–198. [CrossRef]

17. Imai, Y.; Hasegawa, K. The revised Hasegawa’s dementia scale (HDS-R)-Evaluation of its usefulness as a screening test for dementia. J. Aging Res. Clin. Pract. 2012, 1, 193–201.

18. Lee, J.; Park, S.; Lee, J.Y.; Yeo, Y.K.; Kim, J.S.; Lim, J. Improved spatial learning and memory by perilla diet is correlated with immunoreactivities to neurofilament and neurofilament in hilus of dentate gyrus. Proteome Sci. 2012, 10, 1–12. [CrossRef] [PubMed]

19. Hashimoto, M.; Matsuzaki, K.; Kato, S.; Hossain, S.; Ohno, M.; Shido, O. Twelve-month Studies on Perilla frutescens L. Britt. feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: Possible role of neuronal mitochondria metabolism. J. Hong Kong Coll. Psychiatr. 1994, 20, 4–20. [PubMed]

20. Okada, K.; Kobayashi, S.; Aoki, K.; Suyama, N.; Yamagata, S. Assessment of motivational loss in poststroke patients using the Japanese version of Starkstein’s Apathy Scale (in Japanese). Jpn. J. Stroke 2008, 29, 275–289. [CrossRef] [PubMed]

21. Zung, W.W. A SELF-RATING DEPRESSION SCALE. Arch. Gen. Psychiatr. 1965, 12, 63–70. [CrossRef] [PubMed]

22. Hashimoto, M.; Shinozuka, K.; Gamoh, S.; Tanabe, Y.; Hossain, M.S.; Kwon, Y.H.; Hata, N.; Misawa, Y.; Kunitomo, M.; Masumura, S. The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged Japanese adults-Possible Supplement for Mental Health. J. Nutr. 2017, 70, 76–85. [CrossRef] [PubMed]

23. Longvah, T.; Deosthale, Y.G.; Kumar, U.P. Nutritional and short term loco-vegetative evaluation of perilla seed oil. Food Chem. 2000, 70, 13–16. [CrossRef] [PubMed]

24. Blondeau, N.; Nguemeni, C.; Debruyne, D.N.; Piens, M.; Wu, X.; Pan, H.; Hu, X.; Gandin, C.; Lipsky, R.H.; Plumier, J.C.; et al. Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: A versatile potential therapy for stroke. Neuropsychopharmacology 2009, 34, 2548–2559. [CrossRef] [PubMed]

25. Feng, Z.; Zou, X.; Jia, H.; Li, X.; Zhu, Z.; Liu, X.; Bucheli, P.; Balleyre, O.; Hou, Y.; Zhang, W.; et al. Maternal docosahexaenoic acid feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: Possible role of neuronal mitochondria metabolism. Antioxid. Redox Signal. 2012, 16, 275–289. [CrossRef] [PubMed]
Foods 2021, 10, 1130

26. Kim, K.B.; Nam, Y.A.; Kim, H.S.; Hayes, A.W.; Lee, B.M. Alpha-linolenic acid: Nutraceutical, pharmacological and toxicological evaluation. *Food Chem. Toxicol.* 2014, 70, 163–178. [CrossRef]

27. Kamalashirani, C.; Sritiyakul, K.; Pattararachchai, J.; Muengtaweepongsa, S. Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial. *Curr. Alzheimer Res.* 2019, 16, 146–155. [CrossRef]

28. Jansen, E.; Ruskovska, T. Comparative analysis of plasma (anti)oxidative status parameters in healthy persons. *Int. J. Mol. Sci.* 2013, 14, 6106–6115. [CrossRef]

29. Pesce, M.; Tatangelo, R.; La, F.I.; Rizzuto, A.; Campagna, G.; Turli, C.; Ferrone, A.; Franceschelli, S.; Speranza, L.; Patruno, A.; et al. Aging-Related Oxidative Stress: Positive Effect of Memory Training. *Neuroscience* 2018, 370, 246–255. [CrossRef]

30. Hetyey, C.S.; Manczur, F.; Dudás-Györki, Z.; Reiczigel, J.; Ribiczey, P.; Vaj dovich, P.; Vörös, K. Plasma antioxidant capacity in dogs with naturally occurring heart diseases. *J. Vet. Med. A Physiol. Pathol. Clin. Med.* 2007, 54, 36–39. [CrossRef]

31. Zhou, X.J.; Yan, L.L.; Yin, P.P.; Shi, L.L.; Zhang, J.H.; Liu, Y.J.; Ma, C. Structural characterisation and antioxidant activity evaluation of phenolic compounds from cold-pressed Perilla frutescens var. arguta seed flour. *Food Chem.* 2014, 164, 150–157. [CrossRef] [PubMed]

32. Lee, A.Y.; Lee, M.H.; Lee, S.; Cho, E.J. Alpha-Linolenic Acid from Perilla frutescens var. japonica Oil Protects Aβ-Induced Cognitive Impairment through Regulation of APP Processing and Aβ Degradation. *J. Agric. Food Chem.* 2017, 65, 10719–10729. [CrossRef] [PubMed]

33. Hashimoto, M.; Hossain, S.; Al Mamun, A.; Matsuzaki, K.; Arai, H. Docosahexaenoic acid: One molecule diverse functions. *Rev. Biotechnol.* 2017, 37, 579–597. [CrossRef]

34. Crupi, R.; Marino, A.; Cuzzocrea, S. n-3 fatty acids: Role in neurogenesis and neuroplasticity. *Curr. Med. Chem.* 2013, 20, 2953–2963. [CrossRef] [PubMed]

35. Francois, C.A.; Connor, S.L.; Bolewicz, L.C.; Connor, W.E. Supplementing lactating women with flaxseed oil does not increase prescription n-3 fatty acids against impairment of spatial cognitive learning ability in amyloid ε4 Allele Carriers. *Psychopharmacology* 2006, 187, 579–597. [CrossRef]

36. Hashimoto, M.; Tozawa, R.; Katakura, M.; Shahdat, H.; Haque, A.M.; Tanabe, Y.; Gamoh, S.; Shido, O. Protective effects of β-carotene and vitamin E on brain antioxidant capacity in amyloid ε4 allele carriers and zinc status in amyloid ε4 allele carriers. *Nutrition* 2006, 22, 534–538. [CrossRef] [PubMed]

37. Freemantle, E.; Vandal, M.; Tremblay-Mercier, J.; Tremblay, S.; Blach, M.; Ruskovska, T. Comparative analysis of plasma (anti)oxidative status parameters in healthy persons. *Nutrition* 2006, 22, 534–538. [CrossRef] [PubMed]

38. Angelucci, F.; Spalletta, G.; di Iulio, F.; Ciaramella, A.; Salani, F.; Colantoni, L.; Varsi, A.E.; Gianni, W.; Sancesario, G.; Caltagirone, C.; et al. Mindfulness: Associations with Working Memory Function. *Curr. Alzheimer Res.* 2014, 11, 213–220. [CrossRef]

39. Nettiksimmons, J.; Simonsick, E.M.; Harris, T.; Satterfield, S.; Rosano, C.; Yaffe, K.; for the Health ABC Study. The associations between serum brain-derived neurotrophic factor, potential confounders, and cognitive decline: A longitudinal study. *J. Alzheimers Dis.* 2010, 21, 261–268. [CrossRef] [PubMed]

40. Heffernan, A.L.; Chidgey, C.; Peng, P.; Masters, C.L.; Roberts, B.R. The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer’s Disease Cohorts. *J. Mol. Neurosci.* 2016, 60, 316–324. [CrossRef]
50. Alata, W.; Ye, Y.; St-Amour, I.; Vandal, M.; Calon, F. Human apolipoprotein E ε4 expression impairs cerebral vascularization and blood-brain barrier function in mice. *J. Cereb. Blood Flow Metab.* 2015, 35, 86–94. [CrossRef]

51. Theendakara, V.; Peters-Libeu, C.A.; Spilman, P.; Poksay, K.S.; Bredesen, D.E.; Rao, R.V. Direct Transcriptional Effects of Apolipoprotein E. *J. Neurosci.* 2016, 36, 685–700. [CrossRef]

52. Fenesi, B.; Fang, H.; Kovacevic, A.; Oremus, M.; Raina, P.; Heisz, J.J. Physical Exercise Moderates the Relationship of Apolipoprotein E (APOE) Genotype and Dementia Risk: A Population-Based Study. *J. Alzheimers Dis.* 2017, 56, 297–303. [CrossRef] [PubMed]

53. Ward, A.; Crean, S.; Mercaldi, C.J.; Collins, J.M.; Boyd, D.; Cook, M.N.; Arrighi, H.M. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: A systematic review and meta-analysis. *Neuroepidemiology* 2012, 38, 1–17. [CrossRef] [PubMed]

54. Wang, L.; Wang, F.; Liu, J.; Zhang, O.; Lei, P. Inverse Relationship between Baseline Serum Albumin Levels and Risk of Mild Cognitive Impairment in Elderly: A Seven-Year Retrospective Cohort Study. *Tohoku J. Exp. Med.* 2018, 246, 51–57. [CrossRef]

55. Zheng, F.; Yan, L.; Yang, Z.; Zhong, B.; Xie, W. HbA1c, diabetes and cognitive decline: The English Longitudinal Study of Ageing. *Diabetologia* 2018, 61, 839–848. [CrossRef] [PubMed]